Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Cited In for PubMed (Select 19050311)

1.

Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis.

Mortensen MB, Kjolby M, Gunnersen S, Larsen JV, Palmfeldt J, Falk E, Nykjaer A, Bentzon JF.

J Clin Invest. 2014 Dec;124(12):5317-22. doi: 10.1172/JCI76002. Epub 2014 Nov 17.

2.

Evaluation of the effect of andrographolide on atherosclerotic rabbits induced by Porphyromonas gingivalis.

Al Batran R, Al-Bayaty F, Al-Obaidi MM, Hussain SF, Mulok TZ.

Biomed Res Int. 2014;2014:724718. doi: 10.1155/2014/724718. Epub 2014 Aug 18.

3.

L-selectin deficiency decreases aortic B1a and Breg subsets and promotes atherosclerosis.

Gjurich BN, Taghavie-Moghadam PL, Ley K, Galkina EV.

Thromb Haemost. 2014 Oct;112(4):803-11. doi: 10.1160/TH13-10-0865. Epub 2014 Jul 3.

4.

Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.

Wilhelm AJ, Major AS.

Int J Clin Rheumtol. 2012 Oct 1;7(5):527-539.

5.

Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity.

Hilgendorf I, Theurl I, Gerhardt LM, Robbins CS, Weber GF, Gonen A, Iwamoto Y, Degousee N, Holderried TA, Winter C, Zirlik A, Lin HY, Sukhova GK, Butany J, Rubin BB, Witztum JL, Libby P, Nahrendorf M, Weissleder R, Swirski FK.

Circulation. 2014 Apr 22;129(16):1677-87. doi: 10.1161/CIRCULATIONAHA.113.006381. Epub 2014 Jan 31.

6.

Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-/- mice.

Wilhelm AJ, Rhoads JP, Wade NS, Major AS.

Ann Rheum Dis. 2015 Apr;74(4):778-85. doi: 10.1136/annrheumdis-2013-203759. Epub 2014 Jan 6.

7.

Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease.

Madhumitha H, Mohan V, Deepa M, Babu S, Aravindhan V.

Cardiovasc Diabetol. 2014 Jan 3;13:1. doi: 10.1186/1475-2840-13-1.

8.

T cells in atherosclerosis.

Tse K, Tse H, Sidney J, Sette A, Ley K.

Int Immunol. 2013 Nov;25(11):615-22. doi: 10.1093/intimm/dxt043. Review.

9.

Regulatory T cells and Atherosclerosis.

Pastrana JL, Sha X, Virtue A, Mai J, Cueto R, Lee IA, Wang H, Yang XF.

J Clin Exp Cardiolog. 2012 Oct 8;2012(Suppl 12):2.

10.

Immune effector mechanisms implicated in atherosclerosis: from mice to humans.

Libby P, Lichtman AH, Hansson GK.

Immunity. 2013 Jun 27;38(6):1092-104. doi: 10.1016/j.immuni.2013.06.009. Review. Erratum in: Immunity. 2013 Aug 22;39(2):413.

11.

The downstream regulation of chemokine receptor signalling: implications for atherosclerosis.

Patel J, Channon KM, McNeill E.

Mediators Inflamm. 2013;2013:459520. doi: 10.1155/2013/459520. Epub 2013 Apr 14. Review.

12.

C-reactive protein/oxidised low-density lipoprotein/β2-glycoprotein I complex promotes atherosclerosis in diabetic BALB/c mice via p38mitogen-activated protein kinase signal pathway.

Zhang R, Zhou SJ, Li CJ, Wang XN, Tang YZ, Chen R, Lv L, Zhao Q, Xing QL, Yu DM, Yu P.

Lipids Health Dis. 2013 Mar 26;12:42. doi: 10.1186/1476-511X-12-42.

13.

Adaptive immunity in atherogenesis: new insights and therapeutic approaches.

Lichtman AH, Binder CJ, Tsimikas S, Witztum JL.

J Clin Invest. 2013 Jan;123(1):27-36. doi: 10.1172/JCI63108. Epub 2013 Jan 2. Review.

14.

Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs.

Subramanian M, Thorp E, Hansson GK, Tabas I.

J Clin Invest. 2013 Jan;123(1):179-88. doi: 10.1172/JCI64617. Epub 2012 Dec 21.

15.

Incretin hormones as immunomodulators of atherosclerosis.

Alonso N, Julián MT, Puig-Domingo M, Vives-Pi M.

Front Endocrinol (Lausanne). 2012 Sep 7;3:112. doi: 10.3389/fendo.2012.00112. eCollection 2012.

16.

Macrophages, dendritic cells, and regression of atherosclerosis.

Feig JE, Feig JL.

Front Physiol. 2012 Jul 18;3:286. doi: 10.3389/fphys.2012.00286. eCollection 2012.

17.

Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis.

Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, Scott SR, von Vietinghoff S, Galkina E, Miller YI, Acton ST, Ley K.

J Clin Invest. 2012 Sep;122(9):3114-26. doi: 10.1172/JCI61758. Epub 2012 Aug 13.

18.

Macrophage differentiation and function in atherosclerosis: opportunities for therapeutic intervention?

Williams HJ, Fisher EA, Greaves DR.

J Innate Immun. 2012;4(5-6):498-508. doi: 10.1159/000336618. Epub 2012 Apr 27. Review.

19.

Lymphocytes and the adventitial immune response in atherosclerosis.

Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V, McNamara CA.

Circ Res. 2012 Mar 16;110(6):889-900. doi: 10.1161/CIRCRESAHA.111.263186. Review.

20.

A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation.

Fornasa G, Clement M, Groyer E, Gaston AT, Khallou-Laschet J, Morvan M, Guedj K, Kaveri SV, Tedgui A, Michel JB, Nicoletti A, Caligiuri G.

Cardiovasc Res. 2012 Apr 1;94(1):30-7. doi: 10.1093/cvr/cvs076. Epub 2012 Jan 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk